

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

**Efficacy of calcium dobesilate in treating Chinese patients with mild to moderate non-proliferative diabetic retinopathy (CALM-DR): protocol for a single-blind, multicenter, cluster-randomized, controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045256
Article Type:	Protocol
Date Submitted by the Author:	25-Sep-2020
Complete List of Authors:	<p>Hu, Hao; Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, Jiangsu, China, Department of Endocrinology</p> <p>Liu, Jiang; Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, Jiangsu, China, Department of Endocrinology</p> <p>Wang, Duolao; Liverpool School of Tropical Medicine, Department of Clinical Sciences</p> <p>Qiu, Shanhu; Affiliated Zhongda Hospital of Southeast University, Department of Endocrinology</p> <p>Yuan, Yang; Zhongda Hospital, Institute of Diabetes, School of Medicine, Southeast University, Nanjing, Jiangsu, China, Department of Endocrinology</p> <p>Wang, Fenghua; Beijing Tongren Hospital, Capital Medical University and Beijing Ophthalmology &amp; Visual Science Key Lab, Beijing, China, Beijing Tongren Eye Center</p> <p>Sun, Zi-lin; Southeast Univ, Department of Endocrinology</p> <p>Song, Qi; Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd, Xuzhou, China</p> <p>Zhai, Gang; Fushun Eye Hospital, Fushun, China</p>
Keywords:	Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, Clinical trials < THERAPEUTICS, ORAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Efficacy of calcium dobesilate in treating Chinese patients with mild to moderate**  
5  
6 **non-proliferative diabetic retinopathy (CALM-DR): protocol for a single-blind,**  
7  
8 **multicenter, cluster-randomized, controlled trial**  
9  
10

11 Hao Hu<sup>1</sup>, Jiang Liu<sup>1</sup>, Duolao Wang<sup>2</sup>, Shanhu Qiu<sup>1</sup>, Yang Yuan<sup>1</sup>, Fenghua Wang<sup>3</sup>,  
12  
13  
14 Liang Wen<sup>4</sup>, Qi Song<sup>5</sup>, and Zilin Sun<sup>1</sup>  
15  
16  
17

18  
19  
20 <sup>1</sup>Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of  
21  
22 Medicine, Southeast University, Nanjing, Jiangsu, China  
23

24 <sup>2</sup>Global Health Trials Unit, Liverpool School of Tropical Medicine, Liverpool, United  
25  
26  
27 Kingdom  
28

29  
30 <sup>3</sup>Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University  
31  
32 and Beijing Ophthalmology & Visual Science Key Lab, Beijing, China  
33

34  
35 <sup>4</sup>Fushun Eye Hospital, Fushun, China  
36

37  
38 <sup>5</sup>Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd, Xuzhou, China  
39  
40  
41

42  
43 Corresponding author: Zilin Sun  
44

45  
46 Mobile: + 86 13951749490  
47

48  
49 E-mail: sunzilin1963@126.com  
50  
51

52  
53 HH and JL shared first authorship.  
54  
55

56  
57  
58 This manuscript includes 4423 words in main text.  
59  
60

## Abstract

### Introduction

Calcium dobesilate (CaD) has been recommended to treat diabetic retinopathy (DR) due to its potential in protecting against retinal vascular damage. However, there is limited evidence exploring its efficacy in combating DR progression. This study is aimed at evaluating whether CaD could prevent DR progression into an advanced stage among Chinese patients with mild to moderate non-proliferative DR (NPDR).

### Methods and analysis

This study is a single-blind, multicenter, cluster-randomized, controlled superiority trial. A total of 1,200 patients with mild to moderate NPDR will be enrolled and randomly assigned at a 1:1 ratio into the control group (conventional treatment group) and the intervention group (conventional treatment plus CaD [500 mg trice daily] for 12 months). Patients will be followed at 1, 3, 6, and 12 months after randomization and receiving treatments, with the severity of DR assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. The primary endpoint is the progression of DR during follow-up, which is defined as an increase of 2 or more steps in the ETDRS scale. The secondary endpoints include the concomitant changes in visual acuity, presence, number, location and type of retinal lesions, and retinal blood vessel diameter as well as the arteriovenous ratio at different visits.

### Ethics and dissemination

The Ethical Review Committees of Zhongda Hospital of Southeast University has approved the study (2019ZDSYLL132-P01). The results will be published in high

1  
2  
3  
4 impact peer-reviewed scientific journals aimed at the general reader.  
5

6  
7 **Trial registration numbers**

8  
9 NCT04283162.  
10

11  
12 **Strengths and limitations of this study**

13  
14 (1) This will be the first cluster-randomized controlled trial with a large sample size  
15  
16 assessing the efficacy of Calcium dobesilate (CaD) in treating diabetic retinopathy  
17  
18 (DR) among individuals with mild to moderate non-proliferative DR.  
19

20  
21 (2) This study will collect longitudinal data on patients treated with CaD, and will  
22  
23 report on the evolution of several important outcome measures over the first year.  
24  
25

26  
27 (3) As with any longitudinal study, there is a risk of loss to follow-up throughout the  
28  
29 study period, which may induce bias in the final results.  
30

31  
32 (4) A relatively short-term follow-up period of 12 months might also be a limitation  
33  
34 for this study.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Diabetic retinopathy (DR) is a common microvascular complication associated with diabetes, and encompasses a broad clinical spectrum from the mild non-proliferative DR (NPDR) to a more advanced stage of vision-threatening such as proliferative DR (PDR) and diabetic macular edema (DME).<sup>1</sup> The pathogenesis of DR involves a variety of abnormal pathways, which are triggered by a series of factors including chronic hyperglycemia, free radicals, advanced glycosylation end products, inflammatory cytokines, and vascular endothelial growth factors (VEGF).<sup>2</sup> These may eventually lead to blood-retinal barrier (BRB) breakdown, retinal neovascularization, and retinal neuronal apoptosis,<sup>3</sup> with BRB injury being considered the hallmark of DR.<sup>4</sup>

There is evidence that 30-50% of patients with diabetes may develop vision-threatening retinopathy during their lifetime,<sup>5</sup> and that timely intervention, such as intensive diabetes management, adjunctive anti-VEGF therapy, laser photocoagulation, and surgical management, can prevent up to 98% of the cases developing vision loss.<sup>1</sup> However, tight glycaemic control and laser therapy could not reverse the existing ocular damage and may only slow its progression, while ocular surgeries have been questioned regarding its safety as well as its effectiveness in improving visual acuity.<sup>6</sup> Moreover, about three-quarters of the world's diabetic patients live in low-and middle-income countries, where healthcare resources are severely limited,<sup>7</sup> posing a serious challenge to the implementation of anti-VEGF therapy or surgical methods for DR.<sup>2</sup> Therefore, access to affordable medicines,

1  
2  
3  
4 coupled with early detection of DR, may be a better way to prevent and delay diabetic  
5  
6 blindness.<sup>1</sup>  
7

8  
9 CaD is an angioprotective agent that has been proposed as a treatment for DR by  
10  
11 protecting against retinal vascular damage.<sup>8 9</sup> The earliest clinical study was a 2-year,  
12  
13 double-blind, randomized controlled trial (RCT) involving 51 patients and 17  
14  
15 controls. The results showed that CaD was a potent angioprotector, which can prevent  
16  
17 intra and extravascular hemorrhages of retina, reduce the incidence of exudate  
18  
19 formation and improve visual acuity.<sup>10</sup> A recent meta-analysis of 8 RCTs consisting  
20  
21 of 552 patients further demonstrated the angioprotective effects of CaD on the early  
22  
23 stage of DR.<sup>11</sup> However, other studies have reported that CaD had no beneficial effect  
24  
25 on DR.<sup>12-15</sup> One of them focused on the effect of CaD on the development of DME  
26  
27 and was followed up for 5 years. This trial concluded that CaD did not reduce the risk  
28  
29 of developing DME.<sup>14</sup> Therefore, whether CaD is beneficial to DR is unclear.  
30  
31

32  
33 The reason for the discrepancy between clinical trials is unknown. It should be noted  
34  
35 that most of these studies generally have small sample size (range from 18 to 194).<sup>10</sup>  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

12 13 15-21 The sample size of such studies is too small to draw any definitive  
conclusions. Although a most recent study with negative results included a relatively  
large number of participants, however, the primary endpoint of that study was DME.<sup>14</sup>  
As we all know, the first proven effective treatment for DME is macular laser  
photocoagulation or intravitreal injection of anti-VEGF agent,<sup>22</sup> rather than CaD.

Therefore, inconsistencies in the results of these studies may also be attributable to the  
inappropriate choice of primary endpoints. A review clearly identified the need for



1  
2  
3  
4 well-designed, robust trials.<sup>8</sup> We aim to address these problems in the current study.  
5

## 6 **Methods and analysis**

7  
8  
9 This study protocol was guided by the Standard Protocol Items: Recommendations for  
10  
11  
12 Interventional Trials (SPIRIT) reporting guidelines.<sup>23</sup>  
13

### 14 **Trial setting**

15  
16  
17 The trial is a multicenter study set in 24 tertiary hospitals in China. These centers are  
18  
19  
20 located in areas that spans the range of population densities, urbanization and  
21  
22  
23 socioeconomic development status in China.  
24

### 25 **Rationale for using CaD**

26  
27  
28 Despite of the inconsistent results of its efficacy, CaD still remains the only  
29  
30  
31 angioprotective agent that reduces the progression of DR.<sup>24</sup> It was suggested in a  
32  
33  
34 review that some double-blind trials relating to permeability variables had better  
35  
36  
37 results with CaD than placebo, in particular a greater reduction in hemorrhage surface  
38  
39  
40 area and in fluorescein penetration into the vitreous body.<sup>25</sup> Others showed an  
41  
42  
43 improvement of visual acuity after CaD treatment.<sup>25</sup> Another review showed that CaD  
44  
45  
46 had significantly superior effects on the evolution of BRB permeability compared  
47  
48  
49 with placebo.<sup>24</sup> A recent meta-analysis indicated that CaD could effectively treat DR  
50  
51  
52 at the systematic and local ocular levels compared to control.<sup>11</sup>  
53

### 54 **Safety**

55  
56  
57 Safety profiles of CaD have been well-established. Side effects are rare and  
58  
59  
60 uncommon with therapeutic doses of CaD. Uncommon side effect (0.1%-1%) is  
tachycardia. Rare side effects (0.01%-0.1%) include nausea, diarrhea, vomiting, rash,

1  
2  
3  
4 fever, chills, arthralgia, and agranulocytosis.  
5

## 6 **Hypotheses**

7  
8  
9 In relation to the overall objective, the following are the hypotheses: 1) patients with  
10  
11 diabetes who take CaD can reduce the progression of mild to moderate DR; 2) this  
12  
13 intervention can also improve visual acuity and retinal vascular function of these  
14  
15 patients.  
16  
17

## 18 **Objectives**

19  
20 The primary objective of this study is to assess the potential therapeutic effect of CaD  
21  
22 on the progression of mild to moderate DR in adults with diabetes. The secondary  
23  
24 objective is to investigate the effect of the intervention on visual acuity and retinal  
25  
26 vascular changes in these patients.  
27  
28  
29  
30  
31

## 32 **Endpoints**

### 33 **Primary endpoint**

34  
35 The primary endpoint is the progression of DR during 12 months after randomization.  
36  
37 After 12-month treatment, 2 digital fundus photographs will be taken for each eye  
38  
39 according to Early Treatment Diabetic Retinopathy Study (ETDRS) scale standard of  
40  
41 fundus photo description to evaluate the rate of improvement in the progression of  
42  
43 patients with mild to moderate DR. DR progression is defined as an increase of 2 or  
44  
45 more steps on the ETDRS scale during follow-up.<sup>26</sup> The progression of mild to  
46  
47 moderate DR has been widely used in some well-known clinical studies of DR, for  
48  
49 example, DCCT study, ACCORD study, and WESDR study.<sup>1</sup>  
50  
51  
52  
53  
54  
55  
56  
57

### 58 **Secondary endpoints**

- 1
- 2
- 3
- 4 (1) Progression of DR from baseline to 3, 6 and 12 months;
- 5
- 6 (2) Time from randomization to the occurrence of progression of DR;
- 7
- 8
- 9 (3) ETDRS scale at baseline, 3, 6, and 12 months;
- 10
- 11 (4) Changes in eyesight post-intervention from baseline to 1, 3, 6, and 12 months;
- 12
- 13 (5) Changes in the numbers, location, and types of the retinal lesions post-intervention
- 14
- 15 from baseline to 3, 6, and 12 months;
- 16
- 17 (6) Changes in the retinal blood vessel diameter and arteriovenous ratio from baseline
- 18
- 19 to 3, 6, and 12 months;
- 20
- 21 (7) Changes in metabolic biomarkers such as HbA1c post-intervention from baseline
- 22
- 23 to 3, 6, 12 months.
- 24
- 25
- 26
- 27
- 28
- 29

### 30 **Safety endpoints**

- 31
- 32 (1) Changes in physical examination and vital signs before and after treatment;
- 33
- 34 (2) Changes in laboratory parameters (liver, renal function, blood routine, etc.);
- 35
- 36 (3) Adverse events/serious adverse events and their severities.
- 37
- 38
- 39

### 40 **Selection of patients**

#### 41 **Inclusion criteria**

- 42
- 43 (1) Being diagnosed with mild to moderate diabetic retinopathy;
- 44
- 45 (2) Being older than 18 years;
- 46
- 47 (3) Being willing to attend this trial.
- 48
- 49
- 50
- 51
- 52

#### 53 **Exclusion criteria**

- 54
- 55 (1) Being allergic hypersensitive to experimental drugs or comparator drugs;
- 56
- 57 (2) Having alanine aminotransferase or aspartate aminotransferase  $\geq 2$  times higher
- 58
- 59
- 60

- 1  
2  
3  
4 than the upper limit of normal value, or total bilirubin  $\geq 1.5$  times higher than the  
5  
6 upper limit of normal value upon the exclusion of mild fatty liver disease;  
7  
8  
9 (3) Having severe renal insufficiency (defined as an eGFR  $\leq 30$  mL/min/1.73 m<sup>2</sup>);  
10  
11  
12 (4) Having malignant tumor and some other life-threatening diseases;  
13  
14  
15 (5) Being in pregnancy, expecting pregnancy, or breast feeding;  
16  
17 (6) Being with unstable conditions, such as: 1) uncontrolled high blood pressure (e.g.,  
18  
19 BP > 180/100 mmHg); 2) glycosylated hemoglobin (HbA1c) > 8.0% or uncontrolled  
20  
21 high blood glucose or hypoglycemia; 3) acute cardiovascular events like unstable  
22  
23 angina, congestive heart failure, stroke, transient ischemic attack, or myocardial  
24  
25 infarction within the previous 3 months; 4) uncontrolled infection; and 5) diabetic  
26  
27 ketoacidosis or hyperosmolar state in the past 1 month;  
28  
29  
30  
31  
32 (7) Being with glaucoma, cataracts, or other opacities that may interfere with retinal  
33  
34 examination and fundus photography;  
35  
36  
37 (8) Receiving laser treatment, cryocoagulation, or vitrectomy;  
38  
39  
40 (9) Receiving drugs such as CaD or traditional Chinese medicine that may help to  
41  
42 improve micro-vascular function in the past 2 weeks;  
43  
44  
45 (10) Receiving VEGF therapy in the past 4 months or will be judged to take VEGF  
46  
47 therapy because of disease progression;  
48  
49  
50  
51 (11) Having attended other clinical trials in the past 1 month, being attending some  
52  
53 clinical trials, or some other conditions that are unfit for this trial judged by  
54  
55 investigators.  
56  
57

58 Although the recruitment target is mainly middle-aged diabetic patients, the age  
59  
60

1  
2  
3  
4 standard is set at  $\geq 18$  years to include young patients with type 1 diabetes, because of  
5  
6 the prevalence of DR in type 1 diabetes after an average of 23 years is 77-95% despite  
7  
8 adequate treatment for diabetes.<sup>27</sup> The majority of exclusion criteria are based on  
9  
10 reducing the risk of adverse effects associated with the intervention, as well as the rate  
11  
12 of loss of follow-up.  
13  
14

15  
16 Because some drugs may have an effect on DR,<sup>6</sup> patients who have used these  
17  
18 medicines within 1 month will also be excluded.  
19  
20

### 21 22 **Number and source of subjects**

23  
24 It is expected that approximately 1200 patients will be enrolled into the study from the  
25  
26 24 centers (hospitals) in China.  
27  
28

### 29 30 **Screening procedures and pre-randomization investigations**

31  
32 The scope of our study presents a variety of potential barriers to participant  
33  
34 recruitment, for which we will use an assortment of recruitment methods. Our  
35  
36 recruitment strategies will rely on community-level advertising, primary health  
37  
38 service center referrals, and word-of-mouth recommendations of patients treated in  
39  
40 center in order to inform prospective participants of our study. Given that the focus of  
41  
42 this study is on the treatment of DR, it is important to provide potential participants  
43  
44 with an assessment of their retinopathy. We also ensure that participation in treatment  
45  
46 conditions and data collection are convenient for the participants. A member of each  
47  
48 center research team will be in contact with people interested in participating in the  
49  
50 study, screening for eligibility, and explaining the main requirements for participation  
51  
52 in the study. Written information will be sent to the potential participant who are  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 eligible for participation.  
5

6 No research-related procedures will be conducted until detailed written information  
7  
8 about the study is provided to participants and informed consent is obtained. Those  
9  
10 who are still interested in participating in this study after reading the materials will be  
11  
12 invited to a health examination (visit 0): 1) recording of lifestyle characteristics,  
13  
14 including smoking and alcohol; 2) recording of medical history, including glucose-  
15  
16 lowering medications taken within the last 6 months, and other prescription-only  
17  
18 medications taking or have taken in the last month; 3) physical examination, including  
19  
20 measurement of height, body weight, waist and hip circumferences, and vital signs; 4)  
21  
22 laboratory measurements of blood specimens; and 5) a comprehensive eye  
23  
24 examination (see below). Lifestyle education will also be provided.  
25  
26  
27  
28  
29  
30  
31  
32

33 Recruitment of patients will operate for 12 months in total in each center.  
34

### 35 **Randomization and masking**

36  
37 Extensive consultation has been conducted among clinical stakeholders in each  
38  
39 potential center to ensure a willingness to be randomized to one of two interventions  
40  
41 and agreement to implement the allocated plan on a hospital wide level.  
42  
43  
44

45 Randomization will be opened to participants and investigators for safety and  
46  
47 practical considerations, but researchers related to participant's identification,  
48  
49 informed consent acquisition, enrolment, and outcome evaluation will be blinded  
50  
51 about the treatment allocation. 24 hospitals will be randomized to the intervention and  
52  
53 control arms on a 1:1 allocation ratio using a permuted-block randomization method  
54  
55 with block size of four. The allocation sequence will be generated using SAS PROC  
56  
57  
58  
59  
60

1  
2  
3  
4 PLAN independent of the investigators, by the Global Health Trials Unit at the  
5  
6 Liverpool School of Tropical Medicine (UK). This is achieved by the study team  
7  
8 sharing a list of centers, each of which has a corresponding number. Allocation status  
9  
10 will be communicated to the research team coordinator, who will inform respective  
11  
12 centers after the investigators obtain the consents of the participants to participate in  
13  
14 the trial. To ensure that all baseline measurements of allocated interventions by the  
15  
16 investigators are unbiased, the allocation of the intervention groups will be made at  
17  
18 the end of the baseline examination (day -6).  
19  
20  
21  
22  
23

### 24 **Treatment of patients (Figure 1)**

#### 25 **Control group**

26  
27 Participants allocated to the control group are requested not to alter their original  
28  
29 lifestyle habits and treatment plan after randomization and at the end of the study,  
30  
31 with reviews by a study doctor and nurse. Management of blood glucose, blood  
32  
33 pressure, and lipid profiles is undertaken by the study team during the period of the  
34  
35 trial. Any changes to the treatment of these features are made by a doctor who  
36  
37 unaware of treatment allocation to minimize the risk of performance bias. During the  
38  
39 period of this study, patients are treated as appropriate to maintain the following  
40  
41 targets: HbA1c level < 7.5%, blood pressure < 140/80 mmHg, total cholesterol level <  
42  
43 4.0 mmol/L, triglyceride level < 2.0 mmol/L, high-density lipoprotein level > 1.0  
44  
45 mmol/L, and low-density lipoprotein level < 2.0 mmol/L.  
46  
47  
48  
49  
50  
51  
52  
53  
54

#### 55 **Treatment group**

56  
57 Patients in the treatment group will receive the same intervention as those in the  
58  
59  
60

1  
2  
3  
4 control group. Additionally, participants will be asked to take a 1500 mg CaD per day  
5  
6 in three divided doses of 500 mg for one year. The product will be delivered by the  
7  
8 investigator at each center.  
9

### 10 11 **Follow-up of patients**

12  
13  
14 The duration of follow-up after randomization is 12 months. Patients will be seen at  
15  
16 baseline and subsequently at months 3, 6, and 12 by the study team. We have included  
17  
18 extra visits at 1 month to the patients' routine schedule of visits. This extra visit is  
19  
20 intended to re-enforce adherence to study drugs, to re-enforce their understanding of  
21  
22 side effects and the actions that they need to take if these occur, and to examine the  
23  
24 participant clinically.  
25  
26  
27  
28  
29

### 30 31 **Recording and monitoring of adverse events**

32  
33 Adverse events will be recorded by the attending physicians and recorded details  
34  
35 checked by an independent clinically qualified monitor.  
36  
37

### 38 39 **Measures of adherence**

40  
41 Participants in CaD treatment will be asked to bring their study medication to visit 2  
42  
43 (month 1), visit 3 (month 3), visit 4 (month 6), and visit 5 (month 12). The  
44  
45 investigators will examine and register the amounts of tablets taken and thereby assess  
46  
47 compliance to the drug. A compliance rate  $\geq 80\%$  is considered satisfactory.  
48  
49

### 50 51 **Schedule for follow-up/Flow Chart**

52  
53 Eligible participants after screening will be included in the study (visit 1-visit 5)  
54  
55 (Table 1 and Figure 1). Study visits are scheduled for the morning, after an overnight  
56  
57 fast of  $\geq 8$  h and omission of any morning doses of medications. As mentioned above,  
58  
59  
60



1  
2  
3  
4 during the period of randomized treatments, visits are scheduled to occur at baseline  
5  
6 and then after 1, 3, 6 and 12 months ( $\pm 7$  days). For those who are no longer receiving  
7  
8 randomized treatments, they are still scheduled to visit every 6 months, starting from  
9  
10 the baseline visit.  
11  
12

13  
14 At the baseline visit (visit 1), physical examination and blood sampling are repeated,  
15  
16 and the following process are completed: 1) first-morning urine sample for  
17  
18 measurement of urinary albumin/creatinine ratio; 2) visual acuity; 3) retinal  
19  
20 photographs; 4) an examination of concomitant medications; and 5) a review of  
21  
22 current dietary and physical exercise.  
23  
24  
25

26  
27 Routine assessments to be performed when patients receive randomized treatment  
28  
29 include: 1) complete physical examination; 2) laboratory test of fasting blood  
30  
31 samples; 3) urinary albumin/creatinine ratio; 4) visual acuity; 5) retinal photographs;  
32  
33 6) recording of concomitant medications; 7) recording of adverse events; and 8) a  
34  
35 review of current dietary and physical exercise.  
36  
37  
38

#### 39 40 **Public and patient involvement**

41  
42 Patients and/or the public were not involved in the design, or conduct, or reporting, or  
43  
44 dissemination plans of this research.  
45  
46  
47

#### 48 **Assessments**

##### 49 50 **Anthropometric**

51  
52 Height and body weight are measured in light indoor clothing without shoes. Height  
53  
54 and weight are measured to the nearest 0.1 cm and 0.1 kg, respectively. Waist  
55  
56 circumference, the mid-way between lowest rib and iliac crest, hip circumference, and  
57  
58  
59  
60

1  
2  
3  
4 the level of the great trochanters, will be measured to the nearest 0.1 cm. Blood  
5  
6 pressure measurements are taken after at least 5 minutes of rest in duplicate separated  
7  
8 by at least 5 minutes. The mean value of the two measurements will be used in the  
9  
10 analysis. Subjects are required to refrain from smoking or ingesting caffeine for 30  
11  
12 minutes prior to the examination.  
13  
14  
15

### 16 **Sociodemographic**

17 Sociodemographic information, including age, gender, ethnicity, civil status,  
18  
19 education, occupation, income, health history, smoking status and alcohol  
20  
21 consumption, will be collected at baseline.  
22  
23  
24  
25

### 26 **Fasting blood and first-morning urine samples**

27 Fasting blood and first-morning urine samples will be collected and analyzed for  
28  
29 fasting plasma glucose, HbA1c, liver and renal functions, blood lipid profiles, and  
30  
31 urinary albumin/creatinine ratio at baseline and follow-up visits (Table 1).  
32  
33  
34  
35

### 36 **Visual acuity**

37 Visual acuity will be measured in both eyes using ETDRS visual acuity charts at 4 m  
38  
39 by optometrists at baseline and follow-up visits (Table 1).  
40  
41  
42  
43  
44

### 45 **Retinal photographs**

46 All persons with diabetes attending this study will undergo routine digital retinal  
47  
48 photography, which is conducted in a darkened room using a nonmydriatic digital  
49  
50 camera capturing optic disc and macular centered images per eye without the use of  
51  
52 mydriasis by trained and certified photographers.  
53  
54  
55  
56

57 All retinal images from the patients will be independently reviewed and graded by  
58  
59  
60

1  
2  
3  
4 one of three senior retinal graders according to a grading protocol used in the Multi-  
5  
6  
7 Ethnic Study of Atherosclerosis (MESA), which is modified from the Airlie House  
8  
9  
10 Classification system.<sup>28</sup> Levels of DR are classified as no DR (levels 10-13) if no  
11  
12  
13 lesions are detected, and any DR (levels 14-80) when at least one microaneurysm  
14  
15  
16 and/or a blot hemorrhage are detected. DR is further divided into minimal-moderate  
17  
18  
19 NPDR (levels 14-20), mild-moderate NPDR (levels 31-41), and severe NPDR to  
20  
21  
22  
23 proliferative retinopathy (levels 51-80). DME is defined by hard exudates in the  
24  
25  
26 presence of microaneurysms and blot hemorrhage within 1-disc diameter from the  
27  
28  
29 foveal center or the presence of focal photocoagulation scars in the macular area.  
30  
31  
32 Clinically significant macular edema (CSME) is considered present when the macular  
33  
34  
35 edema is within 500  $\mu\text{m}$  of the foveal center or if focal laser photocoagulation scars  
36  
37  
38 are present in the macular area. These are confirmed with central macular thickness  
39  
40  
41 measurements by optical coherence tomography using the macular thickness cube  
42  
43  
44 scan protocol. Vision-threatening retinopathy is defined as the presence of severe  
45  
46  
47 NPDR, proliferative retinopathy, or CSME. The level of retinopathy is graded based  
48  
49  
50 on the worse eye. If an eye is ungradable, the score for the other eye will be used to  
51  
52  
53 define these outcomes.

54  
55  
56 Any discrepancies between the two initial graders will be adjudicated by a senior  
57  
58  
59 grader using standardized edit rules.

### 60 61 62 **Retinal vascular caliber**

63  
64  
65 Retinal vascular caliber is measured using a computer-based program following a  
66  
67  
68 previously validated protocol.<sup>29</sup> Optic disc-centered photograph of the right eye of  
69  
70

1  
2  
3  
4 each participant are measured. Left eye measurements are performed when  
5  
6 photographs of the right eye are ungradable. For each photograph, all arterioles and  
7  
8 venules coursing through an area 0.5 to 1-disc diameter from the optic disc margin are  
9  
10 measured and summarized as the average central arteriolar and venular equivalents.  
11  
12 These equivalents represent the average of projected calibers for the central retinal  
13  
14 vessels, and have a high intergrader repeatability with intra- and inter-grader  
15  
16 intraclass correlation coefficients ranging from 0.78 to 0.99.<sup>30</sup>  
17  
18  
19  
20  
21

### 22 **Procedures for assessing safety**

23  
24 Throughout the course of the study, a steering committee meets to review progress  
25  
26 every 6 months, and an independent data safety monitoring board (DSMB) has been  
27  
28 established to monitor safety and outcomes. The investigators are responsible for  
29  
30 ensuring that all serious adverse events are reported timely to the sponsor, who will  
31  
32 then notify the ethics committee of the corresponding centers and the Chinese  
33  
34 Medicines Agency according to the current laws and ICH/GCP guidelines. In case of  
35  
36 unexpected severe adverse reactions to medication during the study, the trial will be  
37  
38 discontinued. In addition, the DSMB may also recommend termination of the study  
39  
40 for other serious safety reasons.  
41  
42  
43  
44  
45  
46  
47

48 Subjects who withdraw from the study for any reason at any time will not be replaced.  
49  
50 Subjects who are excluded or who decide to stop participating will be referred to their  
51  
52 ophthalmologist for advice on how to manage their DR. At the end of the study, data  
53  
54 on withdrawn subjects will be collected and used for efficacy and safety analyses.  
55  
56  
57

### 58 **Loss to follow-up**

1  
2  
3  
4 All subjects will be followed up for 12 months duration of the trial. Participants will  
5  
6 be sent text message reminders prior to their appointment. If they fail to show, then  
7  
8 they will be contacted by phone or by home visit if phoning is not possible to  
9  
10 understand the reasons and reschedule another appointment within a week.  
11  
12

### 13 14 **Trial closure**

15  
16 Study follow up will be for 12 months following randomization. The trial will be  
17  
18 considered closed after the last patient enrolled has completed 12 months of follow  
19  
20 up.  
21  
22

### 23 24 **Withdrawal from trial intervention**

25  
26 Participants can withdraw from the intervention at any time. Participants may be  
27  
28 withdrawn from the trial at the discretion of the investigator due to a safety concern or  
29  
30 a serious violation of the protocol. Participants will be withdrawn in occurrence of  
31  
32 pregnancy or at the intention to become pregnant. Withdrawn participants will be  
33  
34 invited for the following assessments every 6 months unless written consent is  
35  
36 withdrawn: 1) complete physical examination; 2) fasting blood specimens; 3) visual  
37  
38 acuity; and 4) retinal photographs.  
39  
40  
41  
42  
43  
44

### 45 46 **Statistical methods**

#### 47 48 **Sample size**

49  
50 Progression of DR assessed by an increase of 2 or more steps on the ETDRS severity  
51  
52 scale has not previously been used as primary outcome in RCTs of patients with DR  
53  
54 treated with CaD. A prospective observational cohort study showed that with  
55  
56 conventional treatment, the proportion of patients with 2-step or greater progression  
57  
58  
59  
60

1  
2  
3  
4 of DR at 1 year was 16.2%.<sup>31</sup> It is expected that combined medical therapy of DR in  
5  
6 addition to conventional treatment will reduce the development or progression of DR  
7  
8 by approximately 50%.<sup>1</sup> With a two-sided significance level of 5%, a power of 80%,  
9  
10 and an intracluster correlation coefficient of 0.01,<sup>32</sup> a clinically meaningful difference  
11  
12 in the progression of DR over the 12-month intervention of  $\geq 8.1\%$  between two  
13  
14 groups can be detected with 432 participants in each group. To allow for dropouts as  
15  
16 20%, we plan to include 1200 subjects (600 in each of the two study groups), or 50 in  
17  
18 each cluster.  
19  
20  
21  
22  
23

### 24 **Data management**

25  
26  
27 Subjects will be identified by study ID. Study data will be collected and managed  
28  
29 using the Smart CR secure web-based system<sup>33</sup> developed by Suzhou MetroHealth  
30  
31 Medical Technology, where electronic case report forms (CRF) will be created.  
32  
33

34  
35 During the intervention phase, data will be entered directly into the Smart CR by  
36  
37 study personnel and will be extracted by the investigators or sponsor. The fundus  
38  
39 photograph data will be transmitted electronically from the person performing the  
40  
41 operation to the same certified photographic grader and will be archived on a secure  
42  
43 hard drive with backed up in Southeast University. All blood and urine samples  
44  
45 obtained will be stored in a biobank for future use. Samples will be labelled with a  
46  
47 unique study identifier.  
48  
49  
50  
51

### 52 **Statistical analysis**

53  
54  
55 All statistical analyses will be performed using SAS 9.4 and Stata 14 based on  
56  
57 intention-to-treat principle and in accordance with the CONSORT guidelines for  
58  
59  
60

1  
2  
3  
4 reporting cluster randomized trials. Per-protocol analysis will also be performed as  
5  
6 supplementary analysis.  
7

8  
9 A generalized linear mixed-effects model (GLMMIX) will be fitted to analyze the  
10  
11 primary endpoint. The model will have a binomial distribution and logit link function  
12  
13 and include treatment, time, and interaction between treatment and time as fixed  
14  
15 factors; baseline ETDRS severity scale as covariate, and cluster and subject as  
16  
17 random effects. Odds ratio with its 95% CI at each time point (3, 6 and 12 months)  
18  
19 will be derived, which will also be converted into risk ratio using the mathematical  
20  
21 relationship between odds ratio and risk ratio.<sup>34</sup> A covariate-adjusted analysis of the  
22  
23 primary endpoint will be performed by adding pre-specified covariates at baseline  
24  
25 into GLMMIX. Missing efficacy data will be treated as missing at random and no  
26  
27 imputation will be made, because the GLMMIX model is a likelihood-based  
28  
29 procedure and handles missing at random as ignorable.<sup>35</sup> To evaluate the sensitivity of  
30  
31 the result of this assumption, the multiple imputation method will be used to impute  
32  
33 missing primary endpoint during follow-up. Pre-specified subgroup analyses are  
34  
35 performed to explore the influence of covariates on primary endpoint.  
36  
37  
38  
39  
40  
41  
42  
43  
44

45 For secondary binary outcomes, the similar GLMMIX will be used. For secondary  
46  
47 continuous outcomes, the change from baseline for each of the outcomes will be  
48  
49 modelled using GLMMIX with normal distribution and identity link function and  
50  
51 with treatment, time and interaction between treatment and time as fixed factors,  
52  
53 baseline measurement as covariate, and cluster and subject as random effects. Mean  
54  
55 difference and its 95% CI at each time point will be derived. Time-to-event outcome  
56  
57  
58  
59  
60

1  
2  
3  
4 will be analyzed using Cox proportional hazards regression model with frailty at the  
5  
6 center (cluster) level and treatment as the study variable and intervention effects will  
7  
8 be reported as hazard ratio with 95% CI. Kaplan-Meier plots will also be produced for  
9  
10 the two study arms separately and log-rank test used to compare two time-to-event  
11  
12 curves.  
13  
14

15  
16 Detailed statistical analyses will be described in the statistical analysis plan, which  
17  
18 will be developed and finalized before the database lockup.  
19  
20

### 21 22 **Ethics and dissemination**

23  
24 The study is carried out in accordance with the Helsinki Declaration after approval by  
25  
26 the Ethical Review Committees of Zhongda Hospital of Southeast University  
27  
28 (2019ZDSYLL132-P01).  
29  
30

31  
32 CaD, which has been discovered more than 40 years ago and is registered for the  
33  
34 treatment of DR in more than 20 countries remains, to date, the only angioprotective  
35  
36 agent that reduces the progression of this disease.<sup>24</sup> Although CaD is effective in  
37  
38 animal and/or in vitro models, however, the results of clinical trials are inconsistent. A  
39  
40 large, multicenter study is warranted to provide a definitive conclusion.<sup>11</sup> To our  
41  
42 knowledge, this study is the largest multicenter RCT, and is unique in embedding a  
43  
44 cluster-randomized trial design within an intervention framework to study the  
45  
46 effectiveness of CaD treatment on the progression of mild to moderate NPDR  
47  
48 compared to conventional treatment. The efficacy of the intervention on visual acuity,  
49  
50 the presence, number, location and type of retinal lesions, and retinal blood vessel  
51  
52 diameter as well as arteriovenous ratio will also be tested. Our study will give us an  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 opportunity to explore in depth whether CaD is beneficial for the treatment of mild to  
5  
6 moderate DR. A limitation of this study is the single-blinded study. Patients' knowing  
7  
8 of their treatment groups may have a psychological impact on the trial results.  
9

10  
11 However, the primary endpoint will be assessed by an independent committee and  
12  
13 results regarding the primary endpoint will not be biased.  
14  
15

16  
17 Even in the case of negative results, this trial will produce a large amount of  
18  
19 illuminating data. Investigators will be able to closely monitor progression of DR in  
20  
21 both arms during the 12-month follow-up period. If the treatment of CaD is effective,  
22  
23 it will provide an additional therapy option for comprehensive management of the  
24  
25 diabetic patients with mild to moderate DR.  
26  
27

28  
29 The results of the trial will be analyzed, presented and published as soon as possible at  
30  
31 high-impact peer-reviewed journals and presented at the international scientific  
32  
33 meetings and conferences. Manuscripts will be written in accordance with the  
34  
35 CONSORT guidelines for reporting cluster randomized trials.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Contributors** HH and JL drafted the manuscript. HH, JL, DW, SQ, YY, FW, YW,  
5  
6 QS, and ZS participated in the design and preparation of the study. DW provided  
7  
8 statistical analysis support. DW, SQ, YY, FW, YW, QS, and ZS critically revised the  
9  
10 manuscript's drafts. All authors approved the final version of the manuscript.  
11  
12

13  
14 **Funding** The authors have not declared a specific grant for this research from any  
15  
16 funding agency in the public, commercial or not-for-profit sectors.  
17  
18

19 **Competing interests** None declared.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1 Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. *Diabetes Care* 2017;40:412-18.
- 2 Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. *Ophthalmology* 2018;125:1608-22.
- 3 Qiu AW, Bian Z, Mao PA, et al. IL-17A exacerbates diabetic retinopathy by impairing Muller cell function via Act1 signaling. *Exp Mol Med* 2016;48:e280.
- 4 Leal EC, Martins J, Voabil P, et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. *Diabetes* 2010;59:2637-45.
- 5 Stefansson E, Bek T, Porta M, et al. Screening and prevention of diabetic blindness. *Acta Ophthalmol Scand* 2000;78:374-85.
- 6 Semeraro F, Morescalchi F, Cancarini A, et al. Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. *Diabetes Metab* 2019;Epub ahead of print.
- 7 Song P, Yu J, Chan KY, et al. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. *J Glob Health* 2018;8:01083.
- 8 Liu J, Li S, Sun D. Calcium dobesilate and micro-vascular diseases. *Life Sci* 2019;221:348-53.

- 1  
2  
3  
4 9 Farsa O. Calcium dobesilate in prevention and treatment of diabetic retinopathy.  
5  
6 Diabetic Retinopathy 2012;2012:356.  
7  
8
- 9  
10 10 Salama Benarroch I, Nano H, Pérez H, et al. Assessment of calcium dobesilate in  
11  
12 diabetic retinopathy. A double-blind clinical investigation. Ophthalmologica  
13  
14 1977;174:47-51.  
15  
16
- 17 11 Zhang X, Liu W, Wu S, et al. Calcium dobesilate for diabetic retinopathy: a  
18  
19 systematic review and meta-analysis. Sci China Life Sci 2015;58:101-7.  
20  
21
- 22 12 Daubresse JC, Meunier R, Dumont P. A controlled clinical trial of calcium  
23  
24 dobesylate in the treatment of diabetic retinopathy. Diabete Metab 1977;3:27-30.  
25  
26
- 27 13 Adank C, Koerner F. Calcium dobesilate in diabetic retinopathy. A retrospective  
28  
29 controlled study. Ophthalmologica 1985;190:102-11.  
30  
31
- 32 14 Haritoglou C, Gerss J, Sauerland C, et al. Effect of calcium dobesilate on  
33  
34 occurrence of diabetic macular oedema (CALDIRET study): randomised, double-  
35  
36 blind, placebo-controlled, multicentre trial. Lancet 2009;373:1364-71.  
37  
38
- 39 15 Larsen HW, Sander E, Hoppe R. The value of calcium dobesilate in the treatment  
40  
41 of diabetic retinopathy. A controlled clinical trial. Diabetologia 1977;13:105-9.  
42  
43
- 44 16 Benarroch IS, Brodsky M, Rubinstein A, et al. Treatment of blood hyperviscosity  
45  
46 with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res  
47  
48 1985;17:131-8.  
49  
50
- 51 17 Leite EB, Mota MC, de Abreu JR, et al. Effect of calcium dobesilate on the  
52  
53 blood-retinal barrier in early diabetic retinopathy. Int Ophthalmol 1990;14:81-8.  
54  
55
- 56 18 Vojnikovic B. Hyperviscosity in whole blood, plasma, and aqueous humor  
57  
58  
59  
60

- 1  
2  
3  
4 decreased by doxium (calcium dobesilate) in diabetics with retinopathy and  
5  
6 glaucoma: a double-blind controlled study. *Ophthalmic Res* 1984;16:150-62.  
7  
8  
9 19 Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and  
10  
11 lowers elevated intraocular pressure in patients with diabetic retinopathy and  
12  
13 glaucoma. *Ophthalmic Res* 1991;23:12-20.  
14  
15  
16  
17 20 Javadzadeh A, Ghorbanihaghjo A, Adl FH, et al. Calcium dobesilate reduces  
18  
19 endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with  
20  
21 diabetic retinopathy. *Mol Vis* 2013;19:62-8.  
22  
23  
24  
25 21 Ribeiro ML, Seres AI, Carneiro AM, et al. Effect of calcium dobesilate on  
26  
27 progression of early diabetic retinopathy: a randomised double-blind study.  
28  
29 *Graefes Arch Clin Exp Ophthalmol* 2006;244:1591-600.  
30  
31  
32  
33 22 Moisseiev E, Loewenstein A. Diabetic macular edema: emerging strategies and  
34  
35 treatment algorithms. *Dev Ophthalmol* 2017;60:165-74.  
36  
37  
38 23 Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 Explanation and  
39  
40 Elaboration: Guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.  
41  
42  
43 24 Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of  
44  
45 diabetic retinopathy. *Treat Endocrinol* 2005;4:221-32.  
46  
47  
48 25 Berthet P, Farine JC, Barras JP, et al. Calcium dobesilate: pharmacological  
49  
50 profile related to its use in diabetic retinopathy. *Int J Clin Pract* 1999;53:631-6.  
51  
52  
53 26 Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2  
54  
55 years: secondary analysis of a randomized clinical trial comparing aflibercept,  
56  
57 bevacizumab, and ranibizumab. *JAMA Ophthalmol* 2017;135:558-68.  
58  
59  
60

- 1  
2  
3  
4 27 Hautala N, Hannula V, Palosaari T, et al. Prevalence of diabetic retinopathy in  
5  
6 young adults with type 1 diabetes since childhood: the Oulu cohort study of  
7  
8 diabetic retinopathy. *Acta Ophthalmol* 2014;92:749-52.  
9  
10  
11 28 Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort  
12  
13 in the United States. *Am J Ophthalmol* 2006;141:446-55.  
14  
15  
16 29 Wong TY, Knudtson MD, Klein R, et al. Computer-assisted measurement of  
17  
18 retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation  
19  
20 between eyes, and effect of refractive errors. *Ophthalmology* 2004;111:1183-90.  
21  
22  
23 30 Cheung CY, Hsu W, Lee ML, et al. A new method to measure peripheral retinal  
24  
25 vascular caliber over an extended area. *Microcirculation* 2010;17:495-503.  
26  
27  
28 31 Lim LS, Chee ML, Cheung CY, et al. Retinal vessel geometry and the incidence  
29  
30 and progression of diabetic retinopathy. *Invest Ophthalmol Vis Sci* 2017;58:  
31  
32 BIO200-5.  
33  
34  
35 32 Gao F, Earnest A, Matchar DB, et al. Sample size calculations for the design of  
36  
37 cluster randomized trials: a summary of methodology. *Contemp Clin Trials*  
38  
39 2015;42:41-50.  
40  
41  
42 33 Smart CR - an online web-based clinical trial management system. 2019  
43  
44 <http://yhx.smart-cr.com>.  
45  
46  
47 34 Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio  
48  
49 in cohort studies of common outcomes. *JAMA*. 1998;280:1690-1.  
50  
51  
52 35 Schafer JL. *Analysis of Incomplete Multivariate Data*. London, United Kingdom,  
53  
54 Chapman & Hall. Press 1997.  
55  
56  
57  
58  
59  
60

**Table 1. Trial design, visits and end points.**

Visit	Visit 0	Visit 1	Visit 2	Visit 3	Visit 4	Visit 5
Time (days from the start of intervention)	-14	-6	30	90	180	360
Informed consent	×					
History	×					
Inclusion/exclusion criteria	×					
Height	×	×	×	×	×	×
Body weight	×	×	×	×	×	×
Waist circumference	×	×	×	×	×	×
Hip circumference	×	×	×	×	×	×
Blood pressure	×	×	×	×	×	×
Glycosylated hemoglobin	×	×		×	×	×
Fasting plasma glucose		×				×
Liver function	×	×		×	×	×
Renal function	×	×		×	×	×
Blood lipid profiles		×		×	×	×
Urinary albumin/creatinine ratio		×		×	×	×
Fasting blood samples		×				×
Urine samples		×				×
Visual acuity		×	×	×	×	×
Retinal photographs	×	×		×	×	×
Retinal vascular caliber		×		×	×	×
Adverse events			×	×	×	×
Drug accountability		×	×	×	×	×

The maximum allowed time interval between screening (visit 0) and baseline examination (visit 1) will be 2 weeks (= 14 days). Otherwise, a new screening will be conducted before the participants are included in the study.




Figure 1. Treatment of patient flow chart. BP, blood pressure; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; ACR, urinary albumin/creatinine ratio; TC, total cholesterol, TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

197x227mm (300 x 300 DPI)



# BMJ Open

**Efficacy of calcium dobesilate in treating Chinese patients with mild to moderate non-proliferative diabetic retinopathy (CALM-DR): protocol for a single-blind, multicenter, 24-armed cluster-randomized, controlled trial**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-045256.R1
Article Type:	Protocol
Date Submitted by the Author:	25-Apr-2021
Complete List of Authors:	Hu, Hao; Southeast University, Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine Liu, Jiang; Southeast University, Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine Wang, Duolao; Department of Clinical Sciences, Liverpool School of Tropical Medicine Qiu, Shanhu; Southeast University, Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine Yuan, Yang; Southeast University, Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine Wang, Fenghua; Beijing Tongren Hospital, Capital Medical University and Beijing Ophthalmology & Visual Science Key Lab, Beijing, China, Beijing Tongren Eye Center Wen, Liang; Fushun Eye Hospital Song, Qi; Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd, Xuzhou, China Sun, Zi-lin; Southeast University, Department of Endocrinology, Zhongda Hospital, Institute of Diabetes, School of Medicine
<b>Primary Subject Heading</b>:	Diabetes and endocrinology
Secondary Subject Heading:	Evidence based practice, Diabetes and endocrinology
Keywords:	Diabetic retinopathy < DIABETES & ENDOCRINOLOGY, Clinical trials < THERAPEUTICS, ORAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4 **Efficacy of calcium dobesilate in treating Chinese patients with mild to moderate**  
5  
6 **non-proliferative diabetic retinopathy (CALM-DR): protocol for a single-blind,**  
7  
8 **multicenter, 24-armed cluster-randomized, controlled trial**  
9  
10

11 Hao Hu<sup>1</sup>, Jiang Liu<sup>1</sup>, Duolao Wang<sup>2</sup>, Shanhu Qiu<sup>1</sup>, Yang Yuan<sup>1</sup>, Fenghua Wang<sup>3</sup>,  
12  
13  
14 Liang Wen<sup>4</sup>, Qi Song<sup>5</sup>, and Zilin Sun<sup>1</sup>  
15  
16

17  
18  
19 <sup>1</sup>Southeast University, Department of Endocrinology, Zhongda Hospital, Institute of  
20  
21  
22 Diabetes, School of Medicine, Nanjing, Jiangsu, China  
23

24  
25 <sup>2</sup>Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool,  
26  
27  
28 United Kingdom  
29

30  
31 <sup>3</sup>Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University  
32  
33 and Beijing Ophthalmology & Visual Science Key Lab, Beijing, China  
34

35  
36 <sup>4</sup>Fushun Eye Hospital, Fushun, China  
37

38  
39 <sup>5</sup>Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd, Xuzhou, China  
40  
41

42  
43 Corresponding author: Zilin Sun  
44

45  
46 Mobile: + 86 13951749490  
47

48  
49 E-mail: sunzilin1963@126.com  
50  
51

52  
53  
54 HH and JL shared first authorship.  
55

56  
57  
58 This manuscript includes 4705 words in main text.  
59  
60

## Abstract

### Introduction

Calcium dobesilate (CaD) has been used in the treatment of diabetic retinopathy (DR) due to its potential in protecting against retinal vascular damage. However, there is limited evidence exploring its efficacy in combating DR progression. This study is aimed at evaluating whether CaD could prevent DR progression into an advanced stage among Chinese patients with mild to moderate non-proliferative DR (NPDR).

### Methods and analysis

This study is a single-blind, multicenter, cluster-randomized, controlled superiority trial. A total of 1,272 patients with mild to moderate NPDR will be enrolled and randomly assigned at a 1:1 ratio into the control group (conventional treatment group) and the intervention group (conventional treatment plus CaD [500 mg thrice daily] for 12 months). Patients will be followed at 1, 3, 6, and 12 months after randomization and receiving treatments, with the severity of DR assessed by the Early Treatment Diabetic Retinopathy Study (ETDRS) scale. The primary endpoint is the progression of DR during follow-up, which is defined as an increase of 2 or more steps in the ETDRS scale. The secondary endpoints include the concomitant changes in visual acuity, presence, number, location and type of retinal lesions, and retinal blood vessel diameter as well as the arteriovenous ratio at different visits.

### Ethics and dissemination

Each local ethics committee (first Vote: Ethical Review Committees of Zhongda Hospital of Southeast University (2019ZDSYLL132-P01)) has approved the study.

1  
2  
3  
4 The results will be published in high impact peer-reviewed scientific journals aimed at  
5  
6 the general reader.  
7

### 8 9 **Trial registration numbers**

10  
11 NCT04283162.  
12

### 13 14 **Strengths and limitations of this study**

15  
16  
17 (1) This will be the first cluster-randomized controlled trial with a large sample size  
18  
19 assessing the efficacy of Calcium dobesilate (CaD) in treating diabetic retinopathy  
20  
21 (DR) among individuals with mild to moderate non-proliferative DR.  
22

23  
24  
25 (2) This study will collect longitudinal data on patients treated with CaD, and will  
26  
27 report on the evolution of several important outcome measures over the first year.  
28

29  
30 (3) As with any longitudinal study, there is a risk of loss to follow-up throughout the  
31  
32 study period, which may induce bias in the final results.  
33

34  
35 (4) A relatively short-term follow-up period of 12 months might also be a limitation  
36  
37 for this study.  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Diabetic retinopathy (DR) is a common microvascular complication associated with diabetes, and encompasses a broad clinical spectrum from the mild non-proliferative DR (NPDR) to a more advanced stage of vision-threatening such as proliferative DR (PDR) and diabetic macular edema (DME).<sup>1</sup> The pathogenesis of DR involves a variety of abnormal pathways, which are triggered by a series of factors including chronic hyperglycemia, free radicals, advanced glycosylation end products, inflammatory cytokines, and vascular endothelial growth factors (VEGF).<sup>2</sup> These may eventually lead to blood-retinal barrier (BRB) breakdown, retinal neovascularization, and retinal neuronal apoptosis,<sup>3</sup> with BRB injury being considered the hallmark of DR.<sup>4</sup>

There is evidence that 30-50% of patients with diabetes may develop vision-threatening retinopathy during their lifetime.<sup>5</sup> Timely intervention, such as intensive diabetes management, adjunctive anti-VEGF therapy, laser photocoagulation, and surgical management, can prevent up to 98% of the cases developing vision loss.<sup>1</sup> However, tight glycaemic control and laser therapy could not reverse the existing ocular damage and may only slow its progression. The safety of ocular surgery and its effectiveness in improving visual acuity have also been questioned.<sup>6</sup> Moreover, about three-quarters of the world's diabetic patients live in low-and middle-income countries with severely limited healthcare resources,<sup>7</sup> which poses a serious challenge to the implementation of anti-VEGF therapy or surgical methods for DR.<sup>2</sup> Therefore, access to affordable medicines, coupled with early detection of DR, may be a better way to

1  
2  
3  
4 prevent and delay diabetic blindness.<sup>1</sup>  
5

6 CaD is an angioprotective agent that has been proposed as a treatment for DR by  
7  
8 protecting against retinal vascular damage.<sup>8,9</sup> The earliest clinical study was a 2-year,  
9  
10 double-blind, randomized controlled trial (RCT) involving 51 patients and 17  
11  
12 controls. The results showed that CaD was a potent angioprotector, which can prevent  
13  
14 intra and extravascular hemorrhages of retina, reduce the incidence of exudate  
15  
16 formation and improve visual acuity.<sup>10</sup> A recent meta-analysis of 8 RCTs consisting  
17  
18 of 552 patients further demonstrated the angioprotective effects of CaD on the early  
19  
20 stage of DR.<sup>11</sup> However, other studies have reported that CaD had no beneficial effect  
21  
22 on DR.<sup>12-15</sup> One of them focused on the effect of CaD on the development of DME  
23  
24 and was followed up for 5 years. This trial concluded that CaD did not reduce the risk  
25  
26 of developing DME.<sup>14</sup> Therefore, whether CaD is beneficial to DR is unclear.  
27  
28  
29  
30  
31  
32  
33  
34

35 The reason for the discrepancy between clinical trials is unknown. It should be noted  
36  
37 that most of these studies generally have small sample size (range from 18 to 194).<sup>10</sup>  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

12 13 15-21 The sample size of such studies is too small to draw any definitive  
conclusions. Although a most recent study with negative results included a relatively  
large number of participants, however, the primary endpoint of that study was DME.<sup>14</sup>

As we all know, the first proven effective treatment for DME is macular laser  
photocoagulation or intravitreal injection of anti-VEGF agent,<sup>22</sup> rather than CaD.  
Therefore, inconsistencies in the results of these studies may also be attributable to the  
inappropriate choice of primary endpoints. A review clearly identified the need for  
well-designed, robust trials.<sup>8</sup> We aim to address these problems in the current study.

## Methods and analysis

This study protocol was guided by the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) reporting guidelines.<sup>23</sup>

### Trial setting

The Efficacy of CALcium dobesilate in treating Chinese patients with Mild to moderate non-proliferative Diabetic Retinopathy (CALM-DR) is a multicenter randomized controlled study set in 24 tertiary hospitals in China. These centers are located in areas that spans the range of population densities, urbanization and socioeconomic development status in China. We will recruit patients between June, 2021, and December, 2021. Follow-up will complete in December, 2022.

### Rationale for using CaD

Despite of the inconsistent results of its efficacy, CaD still remains the only angioprotective agent that reduces the progression of DR.<sup>24</sup> It was suggested in a review that some double-blind trials relating to permeability variables had better results with CaD than placebo, in particular a greater reduction in hemorrhage surface area and in fluorescein penetration into the vitreous body.<sup>25</sup> Others showed an improvement of visual acuity after CaD treatment.<sup>25</sup> Another review showed that CaD had significantly superior effects on the evolution of BRB permeability compared with placebo.<sup>24</sup> A recent meta-analysis indicated that CaD could effectively treat DR at the systematic and local ocular levels compared to control.<sup>11</sup>

### Safety

Safety profiles of CaD have been well-established. Side effects are rare and



1  
2  
3  
4 uncommon with therapeutic doses of CaD. Uncommon side effect (0.1%-1%) is  
5  
6 tachycardia. Rare side effects (0.01%-0.1%) include nausea, diarrhea, vomiting, rash,  
7  
8 fever, chills, arthralgia, and agranulocytosis.  
9

## 10 11 **Hypotheses**

12  
13  
14 In relation to the overall objective, the following are the hypotheses: 1) patients with  
15  
16 diabetes who take CaD can reduce the progression of mild to moderate DR; 2) this  
17  
18 intervention can also improve visual acuity and retinal vascular function of these  
19  
20 patients.  
21  
22  
23

## 24 25 **Objectives**

26  
27 The primary objective of this study is to assess the potential therapeutic effect of CaD  
28  
29 on the progression of mild to moderate DR in adults with diabetes. The secondary  
30  
31 objective is to investigate the effect of the intervention on visual acuity and retinal  
32  
33 vascular changes in these patients.  
34  
35  
36

## 37 38 **Endpoints**

### 39 40 **Primary endpoint**

41  
42 The primary endpoint is the progression of DR during 12 months after randomization.  
43  
44 After 12-month treatment, 2 digital fundus photographs will be taken for each eye  
45  
46 according to Early Treatment Diabetic Retinopathy Study (ETDRS) scale standard of  
47  
48 fundus photo description to evaluate the rate of improvement in the progression of  
49  
50 patients with mild to moderate DR. DR progression is defined as an increase of 2 or  
51  
52 more steps on the ETDRS scale during follow-up.<sup>26</sup> The progression of mild to  
53  
54 moderate DR has been widely used in some well-known clinical studies of DR, for  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 example, DCCT study, ACCORD study, and WESDR study.<sup>1</sup>  
5

### 6 **Secondary endpoints**

- 7  
8  
9 (1) Progression of DR from baseline to 3, 6 and 12 months;  
10  
11 (2) Time from randomization to the occurrence of progression of DR;  
12  
13 (3) ETDRS scale at baseline, 3, 6, and 12 months;  
14  
15 (4) Changes in eyesight post-intervention from baseline to 1, 3, 6, and 12 months;  
16  
17 (5) Changes in the numbers, location, and types of the retinal lesions post-intervention  
18  
19 from baseline to 3, 6, and 12 months;  
20  
21 (6) Changes in the retinal blood vessel diameter and arteriovenous ratio from baseline  
22  
23 to 3, 6, and 12 months;  
24  
25 (7) Changes in metabolic biomarkers such as HbA1c post-intervention from baseline  
26  
27 to 3, 6, 12 months.  
28  
29

30  
31  
32  
33  
34 Additional repeat testing at 9 months is warranted for patient with type 1 diabetes.  
35

### 36 **Safety endpoints**

- 37  
38 (1) Changes in physical examination and vital signs before and after treatment;  
39  
40 (2) Changes in laboratory parameters (liver, renal function, blood routine, etc.);  
41  
42 (3) Adverse events/serious adverse events and their severities.  
43  
44  
45  
46  
47

### 48 **Selection of patients**

#### 49 **Inclusion criteria**

- 50  
51 (1) Being diagnosed with mild to moderate diabetic retinopathy;  
52  
53 (2) Being older than 18 years;  
54  
55 (3) Being willing to participate in the trial.  
56  
57  
58  
59  
60

## Exclusion criteria

- (1) Being allergic hypersensitive to experimental drugs or comparator drugs;
- (2) Having alanine aminotransferase or aspartate aminotransferase  $\geq 2$  times higher than the upper limit of normal value, or total bilirubin  $\geq 1.5$  times higher than the upper limit of normal value upon the exclusion of mild fatty liver disease;
- (3) Having severe renal insufficiency (defined as an eGFR  $\leq 30$  mL/min/1.73 m<sup>2</sup>);
- (4) Having malignant tumor and some other life-threatening diseases;
- (5) Being pregnancy, expecting pregnancy, or breast feeding;
- (6) Being with unstable conditions, such as: 1) uncontrolled high blood pressure (e.g., BP > 180/100 mmHg); 2) glycosylated hemoglobin (HbA1c) > 8.0% or uncontrolled high blood glucose or hypoglycemia; 3) acute cardiovascular events like unstable angina, congestive heart failure, stroke, transient ischemic attack, or myocardial infarction within the previous 3 months; 4) uncontrolled infection; and 5) diabetic ketoacidosis or hyperosmolar state in the past 1 month;
- (7) Being with glaucoma, cataracts, or other opacities that may interfere with retinal examination and fundus photography;
- (8) Receiving drugs such as CaD or traditional Chinese medicine that may help to improve micro-vascular function in the past 2 weeks;
- (9) Receiving VEGF therapy in the past 4 months or will be judged to take VEGF therapy because of disease progression;
- (10) Having attended other clinical trials in the past 1 month, being attending some clinical trials, or some other conditions that are unfit for this trial judged by

1  
2  
3  
4 investigators.

5  
6 Although the recruitment target is mainly middle-aged diabetic patients, the age  
7  
8  
9 standard is set at  $\geq 18$  years to include young patients with type 1 diabetes, because of  
10  
11 the prevalence of DR in type 1 diabetes after an average of 23 years is 77-95% despite  
12  
13 adequate treatment for diabetes.<sup>27</sup> The majority of exclusion criteria are based on  
14  
15  
16  
17 reducing the risk of adverse effects associated with the intervention, as well as the rate  
18  
19  
20 of loss of follow-up.

21  
22 Because some drugs (such as corticosteroids, non-steroidal anti-inflammatory drugs,  
23  
24 antioxidants, inflammatory molecule inhibitors, renin-angiotensin system blockers,  
25  
26 and fenofibrate) may have an effect on DR,<sup>6</sup> patients who have used these medicines  
27  
28  
29 within 1 month will also be excluded.

### 30 31 32 **Number and source of subjects**

33  
34  
35 It is expected that approximately 1272 patients will be enrolled into the study from the  
36  
37  
38 24 centers (hospitals) in China.

### 39 40 **Screening procedures and pre-randomization investigations**

41  
42  
43 The scope of our study presents a variety of potential barriers to participant  
44  
45 recruitment, for which we will use an assortment of recruitment methods. Our  
46  
47  
48 recruitment strategies will rely on community-level advertising, primary health  
49  
50 service center referrals, and word-of-mouth recommendations of patients treated in  
51  
52 center in order to inform prospective participants of our study. Given that the focus of  
53  
54  
55 this study is on the treatment of DR, it is important to provide potential participants  
56  
57  
58 with an assessment of their retinopathy. We also ensure that participation in treatment  
59  
60

1  
2  
3  
4 conditions and data collection are convenient for the participants. A member of each  
5  
6 center research team will be in contact with people interested in participating in the  
7  
8 study, screening for eligibility, and explaining the main requirements for participation  
9  
10 in the study. Written information will be sent to the potential participant who are  
11  
12 eligible for participation. Researchers in each hospital will obtain informed consent  
13  
14 signed by the participants.  
15  
16  
17

18  
19 No research-related procedures will be conducted until detailed written information  
20  
21 about the study is provided to participants and informed consent is obtained. Those  
22  
23 who are still interested in participating in this study after reading the materials will be  
24  
25 invited to a health examination (visit 0): 1) recording of lifestyle characteristics,  
26  
27 including smoking and alcohol; 2) recording of medical history, including glucose-  
28  
29 lowering medications taken within the last 6 months, and other prescription-only  
30  
31 medications taking or have taken in the last month; 3) physical examination, including  
32  
33 measurement of height, body weight, waist and hip circumferences, and vital signs; 4)  
34  
35 laboratory measurements of blood specimens; and 5) a comprehensive eye  
36  
37 examination (see below). Lifestyle education will also be provided.  
38  
39  
40  
41  
42  
43  
44

45 Recruitment of patients will operate for 12 months in total in each center.  
46  
47

### 48 **Randomization and masking**

49

50 Extensive consultation has been conducted among clinical stakeholders in each  
51  
52 potential center to ensure a willingness to be randomized to one of two interventions  
53  
54 and agreement to implement the allocated plan on a hospital wide level.  
55  
56

57  
58 Randomization will be opened to participants and investigators for safety and  
59  
60

1  
2  
3  
4 practical considerations, but researchers related to participant's identification,  
5  
6 informed consent acquisition, enrolment, and outcome evaluation will be blinded  
7  
8  
9 about the treatment allocation. 24 hospitals will be randomized to the intervention and  
10  
11 control arms on a 1:1 allocation ratio using a permuted-block randomization method  
12  
13 with block size of four. The allocation sequence will be generated using SAS PROC  
14  
15 PLAN independent of the investigators, by the Global Health Trials Unit at the  
16  
17 Liverpool School of Tropical Medicine (UK). This is achieved by the study team  
18  
19 sharing a list of centers, each of which has a corresponding number. Allocation status  
20  
21 will be communicated to the research team coordinator, who will inform respective  
22  
23 centers after the investigators obtain the consents of the participants to participate in  
24  
25 the trial. To ensure that all baseline measurements of allocated interventions by the  
26  
27 investigators are unbiased, the allocation of the intervention groups will be made at  
28  
29 the end of the baseline examination (day -6).  
30  
31  
32  
33  
34  
35  
36

### 37 **Treatment of patients (Figure 1)**

#### 38 **Control group**

39  
40  
41 Participants allocated to the control group are requested not to alter their original  
42  
43 lifestyle habits and treatment plan after randomization and at the end of the study,  
44  
45 with reviews by a study doctor and nurse. Management of blood glucose, blood  
46  
47 pressure, and lipid profiles is undertaken by the study team during the period of the  
48  
49 trial. Any changes to the treatment of these features are made by a doctor who  
50  
51 unaware of treatment allocation to minimize the risk of performance bias. During the  
52  
53 period of this study, patients are treated as appropriate to maintain the following  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 targets: HbA1c level < 7.5%, blood pressure < 140/80 mmHg, total cholesterol level <  
5  
6 4.0 mmol/L, triglyceride level < 2.0 mmol/L, high-density lipoprotein level > 1.0  
7  
8 mmol/L, and low-density lipoprotein level < 2.0 mmol/L.  
9  
10

### 11 **Treatment group**

12  
13  
14 Patients in the treatment group will receive the same intervention as those in the  
15  
16 control group. Additionally, participants will be asked to take a 1500 mg CaD per day  
17  
18 in three divided doses of 500 mg for one year. The product will be delivered by the  
19  
20 investigator at each center.  
21  
22  
23

### 24 **Follow-up of patients**

25  
26  
27 The duration of follow-up after randomization is 12 months. Patients will be seen at  
28  
29 baseline and subsequently at months 3, 6, and 12 by the study team. We have included  
30  
31 extra visits at 1 month to the patients' routine schedule of visits. This extra visit is  
32  
33 intended to re-enforce adherence to study drugs, to re-enforce their understanding of  
34  
35 side effects and the actions that they need to take if these occur, and to examine the  
36  
37 participant clinically.  
38  
39  
40  
41  
42

### 43 **Recording and monitoring of adverse events**

44  
45 Adverse events will be recorded by the attending physicians and recorded details  
46  
47 checked by an independent clinically qualified monitor.  
48  
49

### 50 **Measures of adherence**

51  
52  
53 Participants in CaD treatment will be asked to bring their study medication to visit 2  
54  
55 (month 1), visit 3 (month 3), visit 4 (month 6), and visit 5 (month 12). The  
56  
57 investigators will examine and register the amounts of tablets taken and thereby assess  
58  
59  
60

1  
2  
3  
4 compliance to the drug. A compliance rate  $\geq 80\%$  is considered satisfactory.  
5

### 6 **Schedule for follow-up/Flow Chart**

7  
8  
9 Eligible participants after screening will be included in the study (visit 1-visit 5)  
10  
11 (Table 1 and Figure 1). Study visits are scheduled for the morning, after an overnight  
12  
13 fast of  $\geq 8$  h and omission of any morning doses of medications. As mentioned above,  
14  
15 during the period of randomized treatments, visits are scheduled to occur at baseline  
16  
17 and then after 1, 3, 6 and 12 months ( $\pm 7$  days). For those who are no longer receiving  
18  
19 randomized treatments, they are still scheduled to visit every 6 months, starting from  
20  
21 the baseline visit.  
22  
23  
24  
25

26  
27 At the baseline visit (visit 1), physical examination and blood sampling are repeated,  
28  
29 and the following process are completed: 1) first-morning urine sample for  
30  
31 measurement of urinary albumin/creatinine ratio; 2) visual acuity; 3) retinal  
32  
33 photographs; 4) an examination of concomitant medications; and 5) a review of  
34  
35 current dietary and physical exercise.  
36  
37  
38  
39

40  
41 Routine assessments to be performed when patients receive randomized treatment  
42  
43 include: 1) complete physical examination; 2) laboratory test of fasting blood  
44  
45 samples; 3) urinary albumin/creatinine ratio; 4) visual acuity; 5) retinal photographs;  
46  
47  
48 6) recording of concomitant medications; 7) recording of adverse events; and 8) a  
49  
50 review of current dietary and physical exercise.  
51  
52

### 53 **Public and patient involvement**

54  
55  
56 Patients and/or the public were not involved in the design, or conduct, or reporting, or  
57  
58 dissemination plans of this research.  
59  
60



## **Implementation quality and intervention fidelity**

To ensure both the quality and motivation, a series of dialogue meetings between project partners were held before and after recruitment of hospitals. Meetings between the project and hospital leaderships, and the intervention implementers were held before and after recruitment, and regular meetings are planned throughout the study period. To ensure intervention fidelity, quarterly gatherings will be organised throughout the project period separately for the hospital leaderships and the study group members of each hospital to share experiences and motivate each other. In each gathering, each hospital is required to develop an execution plan for their specific work the coming quarter. In addition, representatives from project leaderships will phone calls with each team every other week to discuss progress, challenges and solutions.

## **Assessments**

### **Anthropometric**

Height and body weight are measured in light indoor clothing without shoes. Height and weight are measured to the nearest 0.1 cm and 0.1 kg, respectively. Waist circumference, the mid-way between lowest rib and iliac crest, hip circumference, and the level of the great trochanters, will be measured to the nearest 0.1 cm. Blood pressure measurements are taken after at least 5 minutes of rest in duplicate separated by at least 5 minutes. The mean value of the two measurements will be used in the analysis. Subjects are required to refrain from smoking or ingesting caffeine for 30 minutes prior to the examination.

## **Sociodemographic**

Sociodemographic information, including age, gender, ethnicity, civil status, education, occupation, income, health history, smoking status and alcohol consumption, will be collected at baseline.

## **Fasting blood and first-morning urine samples**

Fasting blood and first-morning urine samples will be collected and analyzed for fasting plasma glucose, HbA1c, liver and renal functions, blood lipid profiles, and urinary albumin/creatinine ratio at baseline and follow-up visits (Table 1).

## **Visual acuity**

Visual acuity will be measured in both eyes using ETDRS visual acuity charts at 4 m by optometrists at baseline and follow-up visits (Table 1).

## **Retinal photographs**

All persons with diabetes attending this study will undergo routine digital retinal photography, which is conducted in a darkened room using a nonmydriatic digital camera capturing optic disc and macular centered images per eye without the use of mydriasis by trained and certified photographers.

According to a grading protocol modified by Airlie House Classification system used in the Multi-Ethnic Study of Atherosclerosis (MESA), all retinal images from the patients will be independently reviewed and graded by one of three senior retinal graders who do not know the clinical details.<sup>28</sup> Levels of DR are classified as no DR (levels 10-13) if no lesions are detected, and any DR (levels 14-80) when at least one microaneurysm and/or a blot hemorrhage are detected. DR is further divided into

1  
2  
3  
4 minimal-moderate NPDR (levels 14-20), mild-moderate NPDR (levels 31-41), and  
5  
6 severe NPDR to proliferative retinopathy (levels 51-80). DME is defined as retinal  
7  
8 thickening or hard exudates at least one disc diameter to the center of the macular.  
9  
10 Clinically significant macular edema (CSME), introduced by ETDRS, is defined as  
11  
12 DME meeting at least one of three criteria: thickening at or within 500  $\mu\text{m}$  of the  
13  
14 foveal center, hard exudates within 500 $\mu\text{m}$  of foveal center with adjacent thickening,  
15  
16 or at least one disk diameter of thickening with part of it located within one disc  
17  
18 diameter of foveal center. These are confirmed with central macular thickness  
19  
20 measurements by optical coherence tomography using the macular thickness cube  
21  
22 scan protocol. Vision-threatening retinopathy is defined as the presence of severe  
23  
24 NPDR, proliferative retinopathy, or CSME. The level of retinopathy is graded based  
25  
26 on the worse eye. If an eye is ungradable, the score for the other eye will be used to  
27  
28 define these outcomes.  
29

30  
31 Any discrepancies between the two initial graders will be adjudicated by a senior  
32  
33 grader using standardized edit rules.  
34

### 35 **Retinal vascular caliber**

36  
37 Retinal vascular caliber is measured using a computer-based program following a  
38  
39 previously validated protocol.<sup>29</sup> Optic disc-centered photograph of the right eye of  
40  
41 each participant are measured. Left eye measurements are performed when  
42  
43 photographs of the right eye are ungradable. For each photograph, all arterioles and  
44  
45 venules coursing through an area 0.5 to 1-disc diameter from the optic disc margin are  
46  
47 measured and summarized as the average central arteriolar and venular equivalents.  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 These equivalents represent the average of projected calibers for the central retinal  
5  
6 vessels, and have a high intergrader repeatability with intra- and inter-grader  
7  
8 intraclass correlation coefficients ranging from 0.78 to 0.99.<sup>30</sup>  
9  
10

### 11 **Procedures for assessing safety**

12  
13  
14 Throughout the course of the study, a steering committee meets to review progress  
15  
16 every 6 months, and an independent data safety monitoring board (DSMB) has been  
17  
18 established to monitor safety and outcomes. The investigators are responsible for  
19  
20 ensuring that all serious adverse events are reported timely to the sponsor, who will  
21  
22 then notify the ethics committee of the corresponding centers and the Chinese  
23  
24 Medicines Agency according to the current laws and ICH/GCP guidelines. In case of  
25  
26 unexpected severe adverse reactions to medication during the study, the trial will be  
27  
28 discontinued. In addition, the DSMB may also recommend termination of the study  
29  
30 for other serious safety reasons.  
31  
32  
33  
34  
35  
36  
37

38 Subjects who withdraw from the study for any reason at any time will not be replaced.

39  
40 Subjects who are excluded or who decide to stop participating will be referred to their  
41  
42 ophthalmologist for advice on how to manage their DR. At the end of the study, data  
43  
44 on withdrawn subjects will be collected and used for efficacy and safety analyses.  
45  
46  
47

### 48 **Loss to follow-up**

49  
50 All subjects will be followed up for 12 months duration of the trial. Participants will  
51  
52 be sent text message reminders prior to their appointment. If they fail to show, then  
53  
54 they will be contacted by phone or by home visit if phoning is not possible to  
55  
56 understand the reasons and reschedule another appointment within a week.  
57  
58  
59  
60

## **Trial closure**

Study follow up will be for 12 months following randomization. The trial will be considered closed after the last patient enrolled has completed 12 months of follow up.

## **Withdrawal from trial intervention**

Participants can withdraw from the intervention at any time. Participants may be withdrawn from the trial at the discretion of the investigator due to a safety concern or a serious violation of the protocol. Participants will be withdrawn in occurrence of pregnancy or at the intention to become pregnant. Withdrawn participants will be invited for the following assessments every 6 months unless written consent is withdrawn: 1) complete physical examination; 2) fasting blood specimens; 3) visual acuity; and 4) retinal photographs.

## **Statistical methods**

### **Sample size**

Progression of DR assessed by an increase of 2 or more steps on the ETDRS severity scale has not previously been used as primary outcome in RCTs of patients with DR treated with CaD. A prospective observational cohort study showed that with conventional treatment, the proportion of patients with 2-step or greater progression of DR at 1 year was 15.2% (we contacted the study investigators to clarify the unpublished estimate).<sup>31</sup> It is expected that combined medical therapy of DR in addition to conventional treatment will reduce the development or progression of DR by approximately 50%.<sup>1</sup> With a two-sided significance level of 5%, a power of 80%,

1  
2  
3  
4 and an intracluster correlation coefficient of 0.01,<sup>32</sup> a clinically meaningful difference  
5  
6 in the progression of DR over the 12-month intervention of  $\geq 7.6\%$  between two  
7  
8 groups can be detected with 528 participants in each group. To allow for dropouts as  
9  
10 20%, we plan to include 1272 subjects (636 in each of the two study groups), or 53 in  
11  
12 each cluster.  
13  
14  
15

### 16 **Data management**

17  
18 Subjects will be identified by study ID. Study data will be collected and managed  
19  
20 using the Smart CR secure web-based system<sup>33</sup> developed by Suzhou MetroHealth  
21  
22 Medical Technology, where electronic case report forms (CRF) will be created.  
23  
24 During the intervention phase, data will be entered directly into the Smart CR by  
25  
26 study personnel and will be extracted by the investigators or sponsor. The fundus  
27  
28 photograph data will be transmitted electronically from the person performing the  
29  
30 operation to the same certified photographic grader and will be archived on a secure  
31  
32 hard drive with backed up in Southeast University. All blood and urine samples  
33  
34 obtained will be stored in a biobank for future use. Samples will be labelled with a  
35  
36 unique study identifier.  
37  
38  
39  
40  
41  
42  
43  
44

45 All collected data will only be used for the purposes of the present study. Participants'  
46  
47 information will be confidential and anonymized and will only be treated at a  
48  
49 collective level. Trial results will be shared with both the scientific community and  
50  
51 health professionals, through publications in scientific peer-reviewed journals and  
52  
53 presentations at national and international conferences.  
54  
55  
56  
57

### 58 **Statistical analysis**

1  
2  
3  
4 All statistical analyses will be performed using SAS 9.4 and Stata 14 based on  
5  
6 intention-to-treat principle and in accordance with the CONSORT guidelines for  
7  
8 reporting cluster randomized trials. Per-protocol analysis will also be performed as  
9  
10 supplementary analysis.  
11  
12

13  
14 A generalized linear mixed-effects model (GLMMIX) will be fitted to analyze the  
15  
16 primary endpoint. The model will have a binomial distribution and logit link function  
17  
18 and include treatment, time, and interaction between treatment and time as fixed  
19  
20 factors; baseline ETDRS severity scale as covariate, and cluster and subject as  
21  
22 random effects. Odds ratio with its 95% CI at each time point (3, 6 and 12 months)  
23  
24 will be derived, which will also be converted into risk ratio using the mathematical  
25  
26 relationship between odds ratio and risk ratio.<sup>34</sup> A covariate-adjusted analysis of the  
27  
28 primary endpoint will be performed by adding pre-specified covariates at baseline  
29  
30 into GLMMIX. Missing efficacy data will be treated as missing at random and no  
31  
32 imputation will be made, because the GLMMIX model is a likelihood-based  
33  
34 procedure and handles missing at random as ignorable.<sup>35</sup> To evaluate the sensitivity of  
35  
36 the result of this assumption, the multiple imputation method will be used to impute  
37  
38 missing primary endpoint during follow-up. Pre-specified subgroup analyses are  
39  
40 performed to explore the influence of covariates on primary endpoint.  
41  
42  
43  
44  
45  
46  
47  
48  
49

50 For secondary binary outcomes, the similar GLMMIX will be used. For secondary  
51  
52 continuous outcomes, the change from baseline for each of the outcomes will be  
53  
54 modelled using GLMMIX with normal distribution and identity link function and  
55  
56 with treatment, time and interaction between treatment and time as fixed factors,  
57  
58  
59  
60

1  
2  
3  
4 baseline measurement as covariate, and cluster and subject as random effects. Mean  
5  
6 difference and its 95% CI at each time point will be derived. Time-to-event outcome  
7  
8 will be analyzed using Cox proportional hazards regression model with frailty at the  
9  
10 center (cluster) level and treatment as the study variable and intervention effects will  
11  
12 be reported as hazard ratio with 95% CI. Kaplan-Meier plots will also be produced for  
13  
14 the two study arms separately and log-rank test used to compare two time-to-event  
15  
16 curves.  
17  
18  
19  
20

21  
22 Detailed statistical analyses will be described in the statistical analysis plan, which  
23  
24 will be developed and finalized before the database lockup.  
25  
26

### 27 **Ethics and dissemination**

28  
29 The study is carried out in accordance with the Helsinki Declaration after approval by  
30  
31 each local ethics committee (first Vote: Ethical Review Committees of Zhongda  
32  
33 Hospital of Southeast University (2019ZDSYLL132-P01)). Clinicaltrial.gov  
34  
35 NCT04283162.  
36  
37  
38  
39

40 CaD, which has been discovered more than 40 years ago and is registered for the  
41  
42 treatment of DR in more than 20 countries remains, to date, the only angioprotective  
43  
44 agent that reduces the progression of this disease.<sup>24</sup> Although CaD is effective in  
45  
46 animal and/or in vitro models, however, the results of clinical trials are inconsistent. A  
47  
48 large, multicenter study is warranted to provide a definitive conclusion.<sup>11</sup> To our  
49  
50 knowledge, this study is the largest multicenter RCT, and is unique in embedding a  
51  
52 cluster-randomized trial design within an intervention framework to study the  
53  
54 effectiveness of CaD treatment on the progression of mild to moderate NPDR  
55  
56  
57  
58  
59  
60



1  
2  
3  
4 compared to conventional treatment. The efficacy of the intervention on visual acuity,  
5  
6 the presence, number, location and type of retinal lesions, and retinal blood vessel  
7  
8 diameter as well as arteriovenous ratio will also be tested. Our study will give us an  
9  
10 opportunity to explore in depth whether CaD is beneficial for the treatment of mild to  
11  
12 moderate DR. A limitation of this study is the single-blinded study. Patients' knowing  
13  
14 of their treatment groups may have a psychological impact on the trial results.  
15  
16  
17 However, the primary endpoint will be assessed by an independent committee and  
18  
19 results regarding the primary endpoint will not be biased.  
20  
21  
22

23  
24 Even in the case of negative results, this trial will produce a large amount of  
25  
26 illuminating data. Investigators will be able to closely monitor progression of DR in  
27  
28 both arms during the 12-month follow-up period. If the treatment of CaD is effective,  
29  
30 it will provide an additional therapy option for comprehensive management of the  
31  
32 diabetic patients with mild to moderate DR.  
33  
34  
35

36  
37 The results of the trial will be analyzed, presented and published as soon as possible at  
38  
39 high-impact peer-reviewed journals and presented at the international scientific  
40  
41 meetings and conferences. Manuscripts will be written in accordance with the  
42  
43 CONSORT guidelines for reporting cluster randomized trials.  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 **Contributors** HH and JL drafted the manuscript. HH, JL, DW, SQ, YY, FW, YW,  
5  
6 QS, and ZS participated in the design and preparation of the study. DW provided  
7  
8 statistical analysis support. DW, SQ, YY, FW, YW, QS, and ZS critically revised the  
9  
10 manuscript's drafts. All authors approved the final version of the manuscript.  
11  
12

13  
14 **Funding** This work is supported by the Diabetes fund project of Chinese Society of  
15  
16 Microcirculation. The funding body provides funds for employment of research  
17  
18 assistants, engagement of statistical support, and manuscripts processing fees. It is not  
19  
20 involved in the design of the study, and collection, analysis and interpretation of data,  
21  
22 and in writing of the manuscript.  
23  
24  
25

26  
27 **Competing interests** None declared.  
28  
29  
30  
31

32  
33 Figure 1. Treatment of patient flow chart. BP, blood pressure; HbA1c, glycosylated  
34  
35 hemoglobin; FPG, fasting plasma glucose; ACR, urinary albumin/creatinine ratio; TC,  
36  
37 total cholesterol, TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density  
38  
39 lipoprotein.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

- 1 Solomon SD, Chew E, Duh EJ, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. *Diabetes Care* 2017;40:412-18.
- 2 Wong TY, Sun J, Kawasaki R, et al. Guidelines on diabetic eye care: the International Council of Ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings. *Ophthalmology* 2018;125:1608-22.
- 3 Qiu AW, Bian Z, Mao PA, et al. IL-17A exacerbates diabetic retinopathy by impairing Muller cell function via Act1 signaling. *Exp Mol Med* 2016;48:e280.
- 4 Leal EC, Martins J, Voabil P, et al. Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes. *Diabetes* 2010;59:2637-45.
- 5 Stefansson E, Bek T, Porta M, et al. Screening and prevention of diabetic blindness. *Acta Ophthalmol Scand* 2000;78:374-85.
- 6 Semeraro F, Morescalchi F, Cancarini A, et al. Diabetic retinopathy, a vascular and inflammatory disease: therapeutic implications. *Diabetes Metab* 2019;Epub ahead of print.
- 7 Song P, Yu J, Chan KY, et al. Prevalence, risk factors and burden of diabetic retinopathy in China: a systematic review and meta-analysis. *J Glob Health*

- 1  
2  
3  
4 2018;8:01083.  
5  
6  
7 8 Liu J, Li S, Sun D. Calcium dobesilate and micro-vascular diseases. *Life Sci*  
8  
9 2019;221:348-53.  
10  
11 9 Farsa O. Calcium dobesilate in prevention and treatment of diabetic retinopathy.  
12  
13 *Diabetic Retinopathy* 2012;2012:356.  
14  
15  
16  
17 10 Salama Benarroch I, Nano H, Pérez H, et al. Assessment of calcium dobesilate in  
18  
19 diabetic retinopathy. A double-blind clinical investigation. *Ophthalmologica*  
20  
21 1977;174:47-51.  
22  
23  
24  
25 11 Zhang X, Liu W, Wu S, et al. Calcium dobesilate for diabetic retinopathy: a  
26  
27 systematic review and meta-analysis. *Sci China Life Sci* 2015;58:101-7.  
28  
29  
30 12 Daubresse JC, Meunier R, Dumont P. A controlled clinical trial of calcium  
31  
32 dobesylate in the treatment of diabetic retinopathy. *Diabete Metab* 1977;3:27-30.  
33  
34  
35 13 Adank C, Koerner F. Calcium dobesilate in diabetic retinopathy. A retrospective  
36  
37 controlled study. *Ophthalmologica* 1985;190:102-11.  
38  
39  
40 14 Haritoglou C, Gerss J, Sauerland C, et al. Effect of calcium dobesilate on  
41  
42 occurrence of diabetic macular oedema (CALDIRET study): randomised, double-  
43  
44 blind, placebo-controlled, multicentre trial. *Lancet* 2009;373:1364-71.  
45  
46  
47  
48 15 Larsen HW, Sander E, Hoppe R. The value of calcium dobesilate in the treatment  
49  
50 of diabetic retinopathy. A controlled clinical trial. *Diabetologia* 1977;13:105-9.  
51  
52  
53 16 Benarroch IS, Brodsky M, Rubinstein A, et al. Treatment of blood hyperviscosity  
54  
55 with calcium dobesilate in patients with diabetic retinopathy. *Ophthalmic Res*  
56  
57 1985;17:131-8.  
58  
59  
60

- 1  
2  
3  
4 17 Leite EB, Mota MC, de Abreu JR, et al. Effect of calcium dobesilate on the  
5  
6 blood-retinal barrier in early diabetic retinopathy. *Int Ophthalmol* 1990;14:81-8.  
7  
8  
9 18 Vojnikovic B. Hyperviscosity in whole blood, plasma, and aqueous humor  
10  
11 decreased by doxium (calcium dobesilate) in diabetics with retinopathy and  
12  
13 glaucoma: a double-blind controlled study. *Ophthalmic Res* 1984;16:150-62.  
14  
15  
16 19 Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and  
17  
18 lowers elevated intraocular pressure in patients with diabetic retinopathy and  
19  
20 glaucoma. *Ophthalmic Res* 1991;23:12-20.  
21  
22  
23 20 Javadzadeh A, Ghorbanihaghjo A, Adl FH, et al. Calcium dobesilate reduces  
24  
25 endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with  
26  
27 diabetic retinopathy. *Mol Vis* 2013;19:62-8.  
28  
29  
30 21 Ribeiro ML, Seres AI, Carneiro AM, et al. Effect of calcium dobesilate on  
31  
32 progression of early diabetic retinopathy: a randomised double-blind study.  
33  
34 *Graefes Arch Clin Exp Ophthalmol* 2006;244:1591-600.  
35  
36  
37 22 Moisseiev E, Loewenstein A. Diabetic macular edema: emerging strategies and  
38  
39 treatment algorithms. *Dev Ophthalmol* 2017;60:165-74.  
40  
41  
42 23 Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 Explanation and  
43  
44 Elaboration: Guidance for protocols of clinical trials. *BMJ* 2013;346:e7586.  
45  
46  
47 24 Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of  
48  
49 diabetic retinopathy. *Treat Endocrinol* 2005;4:221-32.  
50  
51  
52 25 Berthet P, Farine JC, Barras JP, et al. Calcium dobesilate: pharmacological  
53  
54 profile related to its use in diabetic retinopathy. *Int J Clin Pract* 1999;53:631-6.  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 26 Bressler SB, Liu D, Glassman AR, et al. Change in diabetic retinopathy through 2  
5  
6 years: secondary analysis of a randomized clinical trial comparing aflibercept,  
7  
8 bevacizumab, and ranibizumab. *JAMA Ophthalmol* 2017;135:558-68.  
9  
10  
11 27 Hautala N, Hannula V, Palosaari T, et al. Prevalence of diabetic retinopathy in  
12  
13 young adults with type 1 diabetes since childhood: the Oulu cohort study of  
14  
15 diabetic retinopathy. *Acta Ophthalmol* 2014;92:749-52.  
16  
17  
18 28 Wong TY, Klein R, Islam FM, et al. Diabetic retinopathy in a multi-ethnic cohort  
19  
20 in the United States. *Am J Ophthalmol* 2006;141:446-55.  
21  
22  
23 29 Wong TY, Knudtson MD, Klein R, et al. Computer-assisted measurement of  
24  
25 retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation  
26  
27 between eyes, and effect of refractive errors. *Ophthalmology* 2004;111:1183-90.  
28  
29  
30 30 Cheung CY, Hsu W, Lee ML, et al. A new method to measure peripheral retinal  
31  
32 vascular caliber over an extended area. *Microcirculation* 2010;17:495-503.  
33  
34  
35 31 Lim LS, Chee ML, Cheung CY, et al. Retinal vessel geometry and the incidence  
36  
37 and progression of diabetic retinopathy. *Invest Ophthalmol Vis Sci* 2017;58:  
38  
39 BIO200-5.  
40  
41  
42 32 Gao F, Earnest A, Matchar DB, et al. Sample size calculations for the design of  
43  
44 cluster randomized trials: a summary of methodology. *Contemp Clin Trials*  
45  
46 2015;42:41-50.  
47  
48  
49 33 Smart CR - an online web-based clinical trial management system. 2019  
50  
51 <http://yhx.smart-cr.com>.  
52  
53  
54 34 Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 in cohort studies of common outcomes. JAMA. 1998;280:1690-1.  
5

- 6  
7 35 Schafer JL. Analysis of Incomplete Multivariate Data. London, United Kingdom,  
8  
9 Chapman & Hall. Press 1997.  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

1 **Table 1. Trial design, visits and end points. Additional visit\* at 9 months is warranted for patient with type 1 diabetes**


Visit	Visit 0	Visit 1	Visit 2	Visit 3	Visit 4	Visit*	Visit 5
Time (days from the start of intervention)	-14	-6	30	90	180	270	360
Informed consent	×						
History	×						
Inclusion/exclusion criteria	×						
Height	×	×	×	×	×	×	×
Body weight	×	×	×	×	×	×	×
Waist circumference	×	×	×	×	×	×	×
Hip circumference	×	×	×	×	×	×	×
Blood pressure	×	×	×	×	×	×	×
Glycosylated hemoglobin	×	×		×	×	×	×
Fasting plasma glucose		×					×
Liver function	×	×		×	×	×	×
Renal function	×	×		×	×	×	×
Blood lipid profiles		×		×	×	×	×
Urinary albumin/creatinine ratio		×		×	×	×	×
Fasting blood samples		×					×
Urine samples		×					×
Visual acuity		×	×	×	×	×	×
Retinal photographs	×	×		×	×	×	×
Retinal vascular caliber		×		×	×	×	×
Adverse events			×	×	×	×	×
Drug accountability		×	×	×	×	×	×

2 The maximum allowed time interval between screening (visit 0) and baseline examination (visit 1) will be 2 weeks (= 14 days). Otherwise, a



1  
2  
3  
4  
5 3 new screening will be conducted before the participants are included in the study.  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only



43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Figure 1. Treatment of patient flow chart. BP, blood pressure; HbA1c, glycosylated hemoglobin; FPG, fasting plasma glucose; ACR, urinary albumin/creatinine ratio; TC, total cholesterol, TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein.

197x227mm (600 x 600 DPI)



SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents\*

Section/item	Item No	Description
<b>Administrative information</b>		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym <b>P1</b>
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry <b>P3 and P22</b>
	2b	All items from the World Health Organization Trial Registration Data Set <b>NA</b>
Protocol version	3	Date and version identifier <b>P22</b>
Funding	4	Sources and types of financial, material, and other support <b>P24</b>
Roles and responsibilities	5a	Names, affiliations, and roles of protocol contributors <b>P1 and P24</b>
	5b	Name and contact information for the trial sponsor <b>P1</b>
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities <b>P24</b>
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee) <b>P18 and P20</b>
<b>Introduction</b>		
Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention <b>P4-5</b>
	6b	Explanation for choice of comparators <b>P4-5</b>
Objectives	7	Specific objectives or hypotheses <b>P7</b>
Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) <b>P6 and P12</b>

## Methods: Participants, interventions, and outcomes

Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained <a href="#">P6</a>
Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists) <a href="#">P8-10</a>
Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered <a href="#">P10-14</a>
	11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease) <a href="#">P18-19</a>
	11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests) <a href="#">P13-15</a>
	11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial <a href="#">P12-13</a>
Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended <a href="#">P7-8</a>
Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) <a href="#">P10-14</a> , <a href="#">P18</a> , and <a href="#">Figure 1</a>
Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations <a href="#">P19-20</a>
Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size <a href="#">P10</a>

## Methods: Assignment of interventions (for controlled trials)

### Allocation:

Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions <a href="#">P11-12</a>
---------------------	-----	---

1			
2	Allocation	16b	Mechanism of implementing the allocation sequence (eg, central
3	concealment		telephone; sequentially numbered, opaque, sealed envelopes),
4	mechanism		describing any steps to conceal the sequence until interventions are
5			assigned P11-12
6			
7	Implementation	16c	Who will generate the allocation sequence, who will enrol participants,
8			and who will assign participants to interventions P11-12
9			
10	Blinding	17a	Who will be blinded after assignment to interventions (eg, trial
11	(masking)		participants, care providers, outcome assessors, data analysts), and
12			how P11-12
13			
14		17b	If blinded, circumstances under which unblinding is permissible, and
15			procedure for revealing a participant's allocated intervention during
16			the trial NA
17			
18			
19			

### Methods: Data collection, management, and analysis

21	Data collection	18a	Plans for assessment and collection of outcome, baseline, and other
22	methods		trial data, including any related processes to promote data quality (eg,
23			duplicate measurements, training of assessors) and a description of
24			study instruments (eg, questionnaires, laboratory tests) along with
25			their reliability and validity, if known. Reference to where data
26			collection forms can be found, if not in the protocol P15-18
27			
28		18b	Plans to promote participant retention and complete follow-up,
29			including list of any outcome data to be collected for participants who
30			discontinue or deviate from intervention protocols P18-19
31			
32	Data	19	Plans for data entry, coding, security, and storage, including any
33	management		related processes to promote data quality (eg, double data entry;
34			range checks for data values). Reference to where details of data
35			management procedures can be found, if not in the protocol P20
36			
37	Statistical	20a	Statistical methods for analysing primary and secondary outcomes.
38	methods		Reference to where other details of the statistical analysis plan can be
39			found, if not in the protocol P20-22
40			
41		20b	Methods for any additional analyses (eg, subgroup and adjusted
42			analyses) P21
43			
44		20c	Definition of analysis population relating to protocol non-adherence
45			(eg, as randomised analysis), and any statistical methods to handle
46			missing data (eg, multiple imputation) P21
47			
48			
49			
50			
51			

### Methods: Monitoring

52			
53	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role
54			and reporting structure; statement of whether it is independent from
55			the sponsor and competing interests; and reference to where further
56			details about its charter can be found, if not in the protocol.
57			Alternatively, an explanation of why a DMC is not needed P18
58			
59			
60			

1			
2		21b	Description of any interim analyses and stopping guidelines, including
3			who will have access to these interim results and make the final
4			decision to terminate the trial P18
5			
6	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and
7			spontaneously reported adverse events and other unintended effects
8			of trial interventions or trial conduct P18-19
9			
10	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and
11			whether the process will be independent from investigators and the
12			sponsor P18
13			
14			

## Ethics and dissemination

15			
16			
17	Research ethics	24	Plans for seeking research ethics committee/institutional review board
18	approval		(REC/IRB) approval P22
19			
20	Protocol	25	Plans for communicating important protocol modifications (eg,
21	amendments		changes to eligibility criteria, outcomes, analyses) to relevant parties
22			(eg, investigators, REC/IRBs, trial participants, trial registries, journals,
23			regulators) P18
24			
25			
26	Consent or assent	26a	Who will obtain informed consent or assent from potential trial
27			participants or authorised surrogates, and how (see Item 32) P11
28			
29		26b	Additional consent provisions for collection and use of participant data
30			and biological specimens in ancillary studies, if applicable NA
31			
32	Confidentiality	27	How personal information about potential and enrolled participants will
33			be collected, shared, and maintained in order to protect confidentiality
34			before, during, and after the trial P20
35			
36			
37	Declaration of	28	Financial and other competing interests for principal investigators for
38	interests		the overall trial and each study site P24
39			
40	Access to data	29	Statement of who will have access to the final trial dataset, and
41			disclosure of contractual agreements that limit such access for
42			investigators P20
43			
44			
45	Ancillary and	30	Provisions, if any, for ancillary and post-trial care, and for
46	post-trial care		compensation to those who suffer harm from trial participation NA
47			
48	Dissemination	31a	Plans for investigators and sponsor to communicate trial results to
49	policy		participants, healthcare professionals, the public, and other relevant
50			groups (eg, via publication, reporting in results databases, or other
51			data sharing arrangements), including any publication restrictions P23
52			
53		31b	Authorship eligibility guidelines and any intended use of professional
54			writers NA
55			
56		31c	Plans, if any, for granting public access to the full protocol, participant-
57			level dataset, and statistical code P20
58			
59			
60			

## Appendices

Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates <a href="#">P11</a> and <a href="#">P20</a>
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable <a href="#">P20</a>

---

\*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "[Attribution-NonCommercial-NoDerivs 3.0 Unported](#)" license.

For peer review only